Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)

v3.8.0.1
Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 06, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Assets:        
Fair value of level 3 financial instruments as of December 31, 2016   $ 3,207    
Viking note receivable fair market value adjustment   (870)    
Cash payment received as partial repayment of note receivable   (200)    
Fair value of level 3 financial instrument assets as of December 31, 2017   3,877 $ 3,207  
Liabilities        
Fair value of level 3 financial instruments as of December 31, 2016   1,604    
Payments to CVR holders and other contingency payments   (4,998) (8,777) $ (6,740)
Fair value adjustments to contingent liabilities   2,500 3,400  
Fair value of level 3 financial instruments as of December 31, 2017   9,990 1,604  
Viking Therapeutics, Inc.        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Quoted market value of equity method investment   25,600    
2019 Convertible Senior Notes | Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of convertible debt   446,400    
Crystal        
Liabilities        
Fair value of Crystal contingent consideration $ 8,401      
Payments to CVR holders and other contingency payments   0 0  
Fair value adjustments to contingent liabilities   0 $ 0  
Cydex        
Liabilities        
Payments to CVR holders and other contingency payments   (25)    
Cydex and Crystal        
Liabilities        
Fair value adjustments to contingent liabilities   $ 10